Q-omics provides the consensus-scored B4GALT7 profile across patient tissues and cancer cell-line models. B4GALT7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, B4GALT7 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, B4GALT7 RNA expression shows 18,209 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, KIRC, and UVM as cancer lineages where B4GALT7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B4GALT7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B4GALT7 survival associations across molecular data types. B4GALT7 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B4GALT7 RNA expression–survival associations across cancer types. High B4GALT7 expression shows unfavorable associations in KIRC, UCS, LIHC, LUSC and LGG, but favorable associations in READ. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for B4GALT7 RNA expression.
This table summarizes B4GALT7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for B4GALT7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B4GALT7 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, LUAD and KIRP. The KIRC box plot shows higher B4GALT7 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with B4GALT7 in patient tissues and cancer cell lines. In patient samples, B4GALT7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, B4GALT7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
